Medical Equipments, Pharmaceuticals And Personal Care Products Tenders

Completion of Non-exclusive Am Discount Agreements According to Section 130a (8) Sgb V by Means of a So-called Oh Model to the Active Ingredient Interferon Beta-1a for Subcutaneous Injection (atc Code According to Who: L03ab07)

Conclusion of Non-Exclusive Discount Agreements According to § 130A Para. 8 Sgb V (Open House Model)

Various Open House Contracts 2023

Conclusion of Non-Exclusive Discount Agreements According to § 130A Paragraph 8 Sgb V for the Active Ingredient Iron Carboxymaltose Iil

Conclusion of Non-Exclusive Discount Agreements According to § 130A Para. 8 Sgb V for the in Ii.2.4. Mentioned Active Ingredients with the Possibility of Conclusion Within the Framework of the So-Called Open-House Procedure.

Conclusion of Non-Exclusive Discount Agreements According to § 130A Para. 8 Sgb V for the Active Ingredient Fingolimod (0.5 Mg)

Conclusion of Non-Exclusive Discount Agreements According to § 130A Para. 8 Sgb V for the in Ii.2.4. Mentioned Active Ingredients with the Possibility of Conclusion Within the Framework of the So-Called Open-House Procedure.

Open House Original Discount Contracts 2023-03

Open Framework Agreement on Drug Discounts in Accordance with § 130A Paragraph 8 Sgb V with the Option to Join at any Time, So-Called Approval Model 2023-03

Completion of a Non-Excl. Discount Agreement According to § 130A Paragraph 8 Sgb V for Formoterol, Budesonide, Atc Code: R03ak07 for the Period from April 1St, 2023 to March 31St, 2025